Co-Authors
This is a "connection" page, showing publications co-authored by Valeria Ghisetti and Andrea Calcagno.
Connection Strength
1.416
-
On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. Front Microbiol. 2021; 12:646679.
Score: 0.234
-
Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. Viruses. 2021 02 11; 13(2).
Score: 0.232
-
Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. Emerg Infect Dis. 2021 Jan; 27(1).
Score: 0.227
-
Co-infection with other respiratory pathogens in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):297-298.
Score: 0.225
-
Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. Antivir Ther. 2017; 22(6):539-543.
Score: 0.176
-
High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. Curr HIV Res. 2017; 15(4):258-265.
Score: 0.175
-
Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. Antivir Ther. 2020; 25(6):327-333.
Score: 0.054
-
Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. Infez Med. 2018 Jun 01; 26(2):160-163.
Score: 0.048
-
The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. Antivir Ther. 2018; 23(5):451-456.
Score: 0.047